Clinical Edge Journal Scan

Erenumab serves as an effective and safe preventive treatment for migraine


Key clinical point: Erenumab may serve as an effective and well-tolerated therapeutic agent for migraine prophylaxis.

Major finding: Compared with placebo, 28 mg (mean difference [MD] 1.1; P = .02), 70 mg (MD 1.4; P < .001), and 140 mg (MD 1.8; P < .001) erenumab led to significant reductions in monthly migraine days at 12 weeks, with each erenumab dose being associated with a significantly higher proportion of patients achieving 50% reduction in migraine days (all P < .001) and similar risk for adverse events.

Study details: This was a systematic review and meta-analysis of eight randomized controlled trials including 4860 patients with migraine who received erenumab (7, 21, 28, 70, or 140 mg) or placebo.

Disclosures: This study was funded by the Jiangsu Province Key Research and Development Program, National Natural Science Foundation of China, and Natural Science Foundation of Jiangsu Province. The authors declared no conflicts of interest.

Source: Gui T, Li H et al. Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials. Headache. 2022;62(10):1281-1292 (Nov 14). Doi: 10.1111/head.14423

Recommended Reading

Prior proton-pump inhibitor use ups migraine risk
Migraine ICYMI
Some patients with resistant chronic migraine may derive long-term benefits with erenumab
Migraine ICYMI
Migraine: Erenumab demonstrates superior efficacy over topiramate
Migraine ICYMI
Real world tolerability of onabotulinum toxin A in chronic migraine
Migraine ICYMI
Phytochemical and polyphenol rich diet reduces migraine severity
Migraine ICYMI